FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

[FierceBiotech @FierceBiotech]

BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships https://t.co/JAgV9bLeVs

[FierceBiotech @FierceBiotech]

UK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors https://t.co/57yAmIPxMn

[FierceBiotech @FierceBiotech]

AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor https://t.co/BQrRXHSjoO

[FierceBiotech @FierceBiotech]

Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset https://t.co/dGcSNhCvdz

[FierceBiotech @FierceBiotech]

Evommune’s phase 2b trial flops, ending challenge to Novartis in hives https://t.co/suvnarLGzB

[FierceBiotech @FierceBiotech]

Ipsen is paying $450 million upfront to buy Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment. https://t.co/NsGv7nkaQB

[FierceBiotech @FierceBiotech]

Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect https://t.co/jMjEddPAkM

[FierceBiotech @FierceBiotech]

With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform https://t.co/SQdTtW0By7

[FierceBiotech @FierceBiotech]

A phase 3b trial of Otsuka’s ADHD prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch of the therapy. https://t.co/Yxestwi4Cf

[FierceBiotech @FierceBiotech]

How a gut feeling transformed cancer treatment forever https://t.co/BtCT940xnr #BIO2026

[FierceBiotech @FierceBiotech]

Amid a bustling fundraising week for biotechs, RQ Bio is adding $115 million to its coffers to advance a long-acting antibody for flu prevention. https://t.co/1KRavfBLFF

[FierceBiotech @FierceBiotech]

Novartis is paying Antares Therapeutics $105 million upfront in a cancer drug discovery deal worth up to $1.9 billion. https://t.co/wwpFJW92h3

[FierceBiotech @FierceBiotech]

Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed a $330 million series B to push its winning contender through a multi-trial phase 3 gauntlet. https://t.co/3hfmFfXu9e

[FierceBiotech @FierceBiotech]

Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact https://t.co/XWSFKkNDSy $LLY

[FierceBiotech @FierceBiotech]

Flagship inks research collaboration with Saudi sovereign wealth fund company https://t.co/KNn32fIuh9 #BIO26

[FierceBiotech @FierceBiotech]

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers https://t.co/d9OHHxmfcp

[FierceBiotech @FierceBiotech]

Pfizer’s high-stakes bet on ADCs has hit a speed bump.
https://t.co/8gd7xSeThV $PFE

[FierceBiotech @FierceBiotech]

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral GLP-1 drug prospect, the company now has more reason to put the money to work. https://t.co/0jEy07uQ3h

[FierceBiotech @FierceBiotech]

Big obesity bets and China's rise fuel potential $2T in 2032 drug sales https://t.co/n64NVcPj7I

[FierceBiotech @FierceBiotech]

Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum https://t.co/gsDiQMlZLf